Targeting PDAC Through a First-in-Class DOCK5 Degrader to Inhibit the RAS Pathway

Time: 2:30 pm
day: Day One Track A PM


  • Showcasing the discovery of a highly selective and potent DOCK5 degrader to target a top dependency of KRAS mt Pancreatic cancer cell lines
  • Displaying how targeted protein degradation of DOCK5 demonstrates anti-tumor activity in KRAS mt PDAC models in vitro and in vivo offering a promising new therapy
  • Exploring how combining a DOCK5deg with direct KRAS-targeting agents reveals superior efficacy in in vitro systems enabling a multi-target approach